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This Senior Design project seeks to manufacture an ​E. Coli​ based antibody for prostate 
cancer detection using unnatural amino acid incorporation. Current diagnostic techniques 
take advantage of the high binding specificity of monoclonal antibodies to detect the 
concentration of prostate specific antigen (PSA) in a blood sample. Production of this 
technology is lengthy and costly, while simultaneously incurring countless ethical problems 
related to animal welfare and accessibility. This project proposes a synthetic antibody that 
can be produced efficiently in single ​E. Coli​  cells and exhibits complementary binding to 
PSA. By incorporating an unnatural amino acid into a recombinant peptide sequence, binding 
affinity between substrate and antibody is substantially increased, effectively expanding the 
genetic code by introducing a novel function. Expression of the antibody is followed by 
extraction and purification of the synthetic antibody from cellular debris. Finally, the 
antibody’s binding strength and specificity to PSA is tested with respect to the monoclonal 
antibody with complementary binding to PSA. Assuming the synthetic antibody has greater 
or equivalent binding affinity than the currently used protein, this project will replace 
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Background, Significance, and Motivation  
Antibodies are natural glycoproteins produced by the immune system that neutralize or 
eliminate foreign invader molecules and organisms. Due to high affinity, specificity, and 
strength in binding to a specific antigen, antibodies enable immune cells to locate and 
terminate target cells. This binding capacity has resulted in the commercialized use of 
antibodies for a variety of research and medical practices, including qualitative and 
quantitative analyses, and mediating or modulating physiological effects. Diagnostic 
applications include Western Blotting, used to increase the sensitivity of an assay system, 
and ELISA, used to analyze soluble antigens.​1​ In these processes, antibodies are manipulated 
to detect the presence of specific proteins, antibodies, or antigens in a sample. Therapeutic 
antibodies are currently used to treat asthma, autoimmune disorders, and cancers, but have 
also been tested for treatment of infectious diseases.​1 
 
Among a myriad of therapeutic and diagnostic applications is the detection of prostate cancer 
using monoclonal antibodies. Prostate cancer is the most common form of cancer among 
white, black, asian, and hispanic men, the second most common among American 
Indian/Alaska Native men, and the second leading cause of cancer death among white, black, 






Figure 1​. ​Overview of prostate cancer statistics 
 
One in nine men will be diagnosed with prostate cancer within his lifetime, while one in 
forty-one men will die from it.​3​ Early detection is crucial: the relative 5-year survival rate for 
the “local stage” in which the disease is contained within the prostate is nearly 100%. 










Detection is done either through a digital rectal exam or by measuring the concentration of 
PSA in the blood.​4​ In the rectal exam, the prostate is assessed for enlarged or abnormal 
physiology. In the blood panel, the level of PSA in the blood is detected using a monoclonal 
antibody. As shown in Figure 1, a healthy prostate secretes a relatively small concentration of 
PSA, part of which is taken up into the bloodstream. However, in those with prostate cancer, 
an elevated level of PSA is secreted and absorbed into the blood.​4 
 
 
Figure 3. Healthy versus disease state related PSA levels. ​Comparison of PSA release from a healthy prostate 
and a prostate with cancer, as well as uptake into the bloodstream. 
 
Monoclonal antibodies currently dominate both the research and medical spheres for 
countless diseases, including prostate cancer. Despite their unique specificity and uniformity, 
the use of monoclonal antibodies raises ethical concerns, presents high contamination risks, 
and requires a lengthy and expensive production process due to the sheer complexity of the 
molecule. While many of these challenges can be overcome by using multiple monoclonal 
antibodies, this route is difficult, expensive, and time consuming.​5  
 
Thus, there is a need for a similarly selective molecule which can be engineered to target 




amino acid incorporation is a promising new technology which will expand the genetic code 
and introduce novel functions into the biological world. By incorporating a non-biologically 
relevant amino acid into a recombinant peptide sequence, a “synthetic antibody” can be 
engineered with specific binding capabilities; and, by designing a synthetic antibody which 
can be produced in ​E. Coli​, there is potential to circumvent the many disadvantages incurred 
through the traditional monoclonal antibody model.  
 
Literature Review 
Unnatural Amino Acid Incorporation 
Unnatural amino acids contain functional groups that are uncommon to the 20 known 
biological amino acids. Bioengineers Wals and Ovaa have explored the various applications 
of unnatural amino acid incorporation through a mutated tRNA synthetase, allowing 
engineers to introduce novel function in proteins by taking advantage of the inherent 
relationship between protein structure and function.​6​ Unnatural amino acid incorporation 
allows selective modification that can be used for therapeutic applications. 
 
Design 
A paper by Umeda et al. explores the possible applications of unnatural amino acid 
incorporation, such as for protein detection probes or therapeutic purposes.​7​ The proposed 
design of the experimental synthetic antibody is partially derived from that of Umeda et al. 
paper. Their system describes the incorporation of an unnatural amino acid, 
3,4-dihydroxy-L-phenylalanine (L-DOPA), to a peptide (TOP1), GFP reporter protein, and a 
6-His purification tag. This project proposes a similar design, but includes a genetically 
engineered sequence specific for PSA, thus pioneering the use of unnatural amino acids for 





Specifically, this design replaces the TOP1 peptide used by Umeda et. al with the 
PSA-specific sequence; however, the principles of unnatural amino acid incorporation are 
generally the same as those outlined in the referenced literature. 
 
 
Figure 4. Synthetic antibody binding PSA. ​Design of the synthetic antibody includes 15 amino acid peptide 
sequence (orange), unnatural amino acid (L-DOPA, black), green fluorescent protein (green), and 6-His 
purification tag (blue). The addition of sodium periodate triggers the formation of a covalent bond (red) between 
the antibody and PSA (purple). 
 
Critiques of Current Literature and Technologies 
Monoclonal antibodies 
Monoclonal antibodies are often used by researchers as drug targets and diagnostic tools 
because they can be used in most every stage when researching protein targets and 
characterization. However, the production of monoclonal antibodies incurs questionably 
ethical practices. To avoid jeopardizing human safety, production of monoclonal antibodies 
is done in animals, typically mice, using the hybridoma model. The hybridoma model 
involves injecting live animals which disease agents in order to induce an immune response, 
leading to antibody synthesis. The antibodies are then extracted through an extensive process 
which often causes excessive distress in the animal.​8​ These practices present a clear need for 






One potential alternative is polyclonal antibodies, which uphold identical structure and 
specificity as the monoclonal counterpart, while requiring less time for production at a 
significantly lower cost. However, they maintain the same ethical pitfalls as monoclonal 
antibodies because they must also be produced in animals. Also, there is batch to batch 
variability in polyclonal antibody production, as well as potential for cross reactivity because 
the antibodies are able to recognize multiple epitopes, unlike monoclonal antibodies.​1 
 
Aptamers 
Aptamers have also been considered as another potential alternative to monoclonal 
antibodies. They are short molecules of either RNA or single-stranded DNA that are capable 
of folding into 3-D conformations which can bind specific target proteins. Aptamers are 
much smaller than monoclonal antibodies and can be synthesized by simpler chemical 
mechanisms, but they are not a viable alternative to monoclonal antibodies because they lack 
stability over ranges of temperature and pH, and in the presence of commonly used buffers.​9 
 
Protein scaffolds 
Protein scaffolds are formed from fragmented polypeptides and can also demonstrate 
similarly specific binding to target molecules. However, similarly to aptamers, protein 
scaffolds are not able to maintain a stable structure over a range of conditions. They also lack 




The goal of this project is to engineer a synthetic antibody for prostate cancer detection as a 




preliminary cloning and sequencing of the plasmid is complete, this project will focus on the 
production and testing of the synthetic antibody.  
 
Toxicity screening must be done first in order to ensure that proper expression of the 
engineered plasmid in ​E. Coli ​is possible with the additional synthetic components. Next, the 
synthetic antibody is isolated through a protein purification method known as manual affinity 
chromatography. Finally, the protein will be analyzed for binding affinity, specificity, and 
selectivity toward PSA and statistically compared to mAb. This validation step is crucial to 
proving viability of the proposed synthetic antibody as an ethical and effective replacement 
of mAb; the former must have equivalent, or greater, diagnostic capabilities as the previously 
established standard method in order to be considered as a possible replacement. 
 
This project focuses on the incorporation of an unnatural amino acid into a peptide which 
specifically codes for PSA binding. This amino acid and the PSA specific sequence are not 
part of the bacteria’s biological code; thus, this molecule is considered a synthetic antibody. 
Because this system is produced in ​E. Coli​ and has potential to assist in prostate cancer 
detection, it serves as a model for the development of additional synthetic antibodies which 
may replace monoclonal antibodies as the gold standard in detection. This model will 
hopefully be able to overcome the challenges of mAb discussed previously as it will incur 
fewer costs, shorter production times, and greater scalability, while maintaining comparable 
functionality. 
 
Overall Design  
A synthetic antibody manufactured in ​E. Coli​ presents three main advantages which 
overcome the challenges associated with monoclonal antibody use and production. The 
proposed synthetic antibody will be more cost efficient than the monoclonal antibody 
counterpart, be ethically produced, and will contain no batch to batch variability between 




sequence which is complementary to the PSA sequence, the replication machinery necessary 
for unnatural amino acid incorporation of L-DOPA, a GFP reporter protein, and a 6-His 
purification tag.  
 
Peptide Sequence 
The P2 peptide sequence was computationally designed by Jon Henry Therriault and Thomas 
Evans using an open source software called Chimera.​11​  The peptide sequence was screened 
against anti-PSA monoclonal antibodies to have high binding affinity (3.5 μM) and 
specificity to PSA.​12 
 
L-DOPA Incorporation 
The second component of the synthetic antibody is an unnatural amino acid called 
3,4-dihydroxy-L-phenylalanine (L-DOPA). L-DOPA is a derivative of tyrosine and it has 
been demonstrated that it can be incorporated in recombinant proteins in ​E. Coli​ by 
suppressing the amber stop codon, which has the codon sequence TAG.​7​ The unnatural 
amino acid is able to form a stable covalent bond with a protein of choice, in this case PSA, 
upon exposure to NaIO​4​.​7​ The L-DOPA is incorporated with a mutant tRNA and tRNA 
synthetase, which are present in the engineered plasmids, in order to have successful 
incorporation of the amino acid.​11  
 
GFP Reporter/Payload 
Additionally, a GFP reporter protein is included in the gene sequence to visualize expression 
of the synthetic antibody using UV light. This method of visualization and validation is 
straightforward, simple to use, and a reliable, commonly used method to determine whether 






Finally, a sequence of 6 consecutive histidines is placed in the gene sequence to aid in 
protein purification. The 6-His tag is used to facilitate the protein purification by using 
immobilized metal-affinity chromatography.​13​ Histidine has previously been established as 
the amino acid with the most efficient retainment to the chromatography matrices.​13  
 
Plasmid Overview 
In total there are two plasmids that are transformed into the ​E. Coli ​competent cells: 
pAC-DHPheRS-6TRN plasmid and pET28b plasmid. The first plasmid has the L-DOPA 
unnatural amino acid production sequence, including the mutant tRNA and tRNA synthetase, 
and a Tet resistance gene. The second plasmid contains the GFP, 6-His tag, the P2 peptide 
sequence, and a Kan resistance gene. The resistance genes are used as a verification for 
successful transformation of both plasmids into the ​E. Coli​ cells, which will be discussed 
further in the following sections.​11  
 
Milestones and Expected Results 
The two plasmids were successfully designed, cloned, and transformed into ​E. Coli 
competent cells by a previous senior design team.​11​ The first milestone of this project is to 
successfully express the synthetic antibody in ​E. Coli ​cells​.​ Here, different growth conditions 
will need to be tested in order to optimize an adequate environment in which the cells will 
not recognize the unnatural amino acid as a foreign entity and commence an apoptotic 
sequence.  
 
Once the expression is successful, the next step is to purify the protein from the ​E. Coli​. The 
purification must be done multiple times using the gold standard of monoclonal antibody 
purification as a representative model. The process will need to highly effective and 





The final step, once the expression and purification of the synthetic antibody is complete, is 
to test the binding capabilities of the engineered synthetic antibody. In order to prove the 
advantage of using a synthetic antibody over a monoclonal antibody, it must be tested for 
binding strength, specificity, and sensitivity for PSA. The standards for the anti-PSA 
monoclonal antibody are already well established and can be used as benchmark 
measurements for the synthetic antibody. 
 
Team Management 
To ensure continuous efficiency and culpability from each team member throughout the 
project, responsibilities will be distributed throughout the team. Cassandra is the primary 
liaison with the School of Engineering, manages the team finances, and ensures all deadlines 
are met. Kimberley coordinates meeting and laboratory scheduling for the team and 
facilitates communications with the advisor, Dr. Zhang. Tatum supervises all writing and 
editing for assignments and presentations, as well as the final report. 
 
Budget 
Through funding granted from the School of Engineering, the project has a $1,500 budget for 
the year. We have $300 allocated for ten reactions using TOP10 competent cells. A $400 
budget for reagents including: buffers, media, our protein target, and monoclonal antibodies. 
To ensure that no genetic mutations occurred within our ​E.coli​ production system, we have 
$90 for DNA sequencing analysis of our 45 nucleotide synthetic antibody. For protein 
purifications, we have $500 allocated to cover the cost of protein gels and purification beads. 
Finally, we estimate our consumables to cost approximately $210, which will cover dialysis 
cassettes, filters, petri dishes, pipette tips, and other items needed for laboratory research. We 
do not anticipate any issues to arise within our budget as we have accounted for additional 






During the Fall term, we initiated toxicity screening and ​E. Coli​ expression. However, due to 
the anticipated challenges of cell survival associated with the mutant tRNA synthetase, our 
toxicity screening will run into the next term as we attempt to narrow in on the ideal 
conditions to avoid cytotoxic responses. Additionally, within the Winter term, we will be 
running the protein purifications and validation screening. Finally, during the Spring term, 
we plan to finalize our results with quantitative analysis and any needed troubleshooting. We 





Chapter 1: Protein Expression 
 
Introduction 
The proposed synthetic antibody has been designed to make use of the highly conserved lac 
operon. In a biological system, the complexly regulated lac operon stimulates lactose 
metabolism. Because it is among the most well-understood operons, protein engineering 
techniques often make use of it to produce recombinant proteins. Production of the L-DOPA 
incorporated synthetic antibody in ​E. Coli​ first requires design of a plasmid which contains 
the desired sequence within the lac operon transcription region. By mimicking the biological 
system’s promoter and repressor functions, expression of the desired sequence can be easily 




Figure 5​. ​Induction of lac operon with IPTG.​ Release of inhibitor from operator site using IPTG, instead of 






Although expression protocols are well established and documented, it is not a simple task to 
accomplish using unnatural amino acids and mutant translation machinery. The main concern 
at this critical step is the lack of ​E. Coli​ growth. In order to ensure optimal growth, multiple 
carbon sources including glycerol and glucose will be introduced at varying concentrations to 
optimize cell growth.  
 
Materials and Methods 
Plasmid Validation 
The first step in this project is to validate that the experimental plasmids have been properly 
transformed into the ​E. Coli ​competent cells by plating the cells with specific antibiotics. The 
pAC-DHPheRS-6TRN plasmid contains the mutant tRNA and tRNA synthetase needed for 
unnatural amino acid incorporation as well as the tetracycline resistance gene. The 
pET28b-P1+TAG+GFP+His contains an enhanced GFP reporter protein, the specific 
sequence which will bind to PSA, a 6 Histidine purification tag, and kanamycin resistance 







Tetracycline + Kanamycin Yes 





Because the cells did not grow in the negative control (ampicillin) but did grow when plated 




Figure 6​. ​Plated TOP10 competent cells.​ Experimental cells containing plasmids  
pAC-DHPheRS-6TRN and pET28 (left) and control cells (right).  
 
Toxicity Response 
The plated cells above show the differences in colony growth between the experimental and 
control. The plated cells on the left contain both experimental plasmids, which include a 
TAG codon sequence which signals for the addition of the unnatural amino acid, L-DOPA, 
into the growing peptide sequence. The cells on the right contain a GCG codon sequence in 
place of the TAG, which codes for an alanine amino acid residue. Because the control 
contains only biologically relevant amino acids, there is no toxicity response evident in the 
size and shape of the cell colonies. By comparing the colonies on both plates, it is evident by 
the small and slightly misshapen colonies on the left that there is a toxicity response based on 
the synthetic nature of the experimental peptide sequence. This indicates that an optimized 





Optimized Antibody Expression Protocol 
The optimized antibody expression protocol was developed from a similar design described 
in a paper by Umeda et. al. First, 500 microliters of glycerol stock containing the 
experimental competent cells were added to 250 milliliters of M9 salts with 5% glucose as 
the carbon source. Thirty and twenty-five micrograms per milliliter of Kanamycin and 
Tetracycline, respectively, were subsequently added. This culture was grown in a dark 
incubator at 37°C with agitation. Once an optimal OD​600​ is reached, 1 mM L-DOPA was 
added for unnatural amino acid incorporation. Agitation at 37°C continues for 40 minutes, at 
which point 1 mM IPTG is added. Once induction with IPTG begins, the temperature is 
lowered to 30°C, and shaking continues for an additional six hours. Finally, the cultures are 







Figure 7.​ ​Expression visualization under UV light.​ Experimental cultures, with L-DOPA incorporation (1) 





Flasks 1 and 2 contain ​E. Coli​ competent cells transformed with the synthetic antibody 
experimental plasmid. Flask 1 contains L-DOPA, which was added once the cells reached 
OD​600​ of 0.4, while flask 2 does not contain L-DOPA. Both flasks 1 and 2 contain IPTG in 
order to induce antibody expression. Green fluorescence indicates successful expression of 
the synthetic antibody with unnatural amino acid incorporation due to the strategic placement 
of GFP at the end of the experimental plasmid. As may not be clear in Figure 7, flask 1 
fluoresces brighter than flask 2. This is to be expected because flask 1 contains the 




The growth of colonies on both culture plates, each with Kanamycin and Tetracycline 
antibiotics, demonstrated the successful transformation of both pAC-DHPheRS-6TRN 
(containing a Tetracycline resistance gene) and pET28 (containing a Kanamycin resistance 
gene) plasmids. The visible variation in colony size suggests that the cultures with TAG are 
expressing an expected toxicity response. This toxicity response must be diligently addressed 
during the antibody expression step. 
 
Toxicity Response 
Due to the toxicity response caused by mutant tRNA and tRNA synthetase, cell growth and 
subsequent antibody expression proved challenging. Multiple expression protocols were 
executed to determine which protocol would optimize cell growth and expression.  
 
First, a traditional growth protocol was followed in which 500 microliters of glycerol stock 
containing the competent cells of interest were grown in minimal media. Optimal growth was 
expected after approximately 24 hours. However, after incubation for 72 hours, the cells 





Next, a similar protocol was conducted in which an additional carbon source, glycogen, was 
added to the culture during growth. Similar to the first protocol, optimal cell growth was not 
reached, even after multiple executions and extended incubation. 
 
Following approximately 10 weeks of troubleshooting, the optimal protein expression 
protocol was reached. It was determined that adding glucose to the growth media, along with 
M9 salts, effectively disguised the mutant tRNA and tRNA synthetase, preventing the cells 
from signaling for apoptosis. Using this protocol, it was possible to grow the cells to optimal 
concentration, following which the antibody could be expressed using induction with IPTG. 
Thus, by adding an additional carbon source, glucose, the cells were able to bypass their 













Figure 8. Bacterial growth curves​. Comparison between initial growth curve (without added carbon source), 





As shown in Figure 8, adding glucose as an additional carbon source did not entirely combat 
the toxicity response caused by the synthetic antibody. This can be determined by the fact 
that the cell’s logarithmic growth phase ended prematurely, transitioning to the stationary 
phase before reaching OD​600​ of 0.6, which is the typically desired optical density. However, 
for the purposes of this project, an OD​600​ of 0.4 will suffice for subsequent antibody 
expression. Thus, the protocol containing glucose as an additional carbon source was 
determined to be the optimized protocol for cell growth and antibody expression. 
 
Antibody Expression 
The validation of a successful protein expression is the signature green illumination from 
GFP. Based on Figure 7, the ​E. Coli ​cells were able to successfully synthesize and express 
the synthetic antibody. The flask on the left has a high level of fluorescence, indicating that 
the plasmids have been fully expressed and that the synthetic antibody is being produced. 
The flask on the right does not contain L-DOPA, but still appears to fluorescence. However, 
this is because all living cells emit baseline fluorescence, so this is not of concern. Thus, 




Chapter 2: Protein Purification 
 
Introduction 
In order to quantify the binding affinity and activity of the synthetic antibody, the protein 
must be extracted and purified. Immobilized Metal Affinity Chromatography (IMAC) will be 
used to purify the protein by taking advantage of the 6-His tag incorporated into the synthetic 
antibody. This technique will allow the purification tag to bind to Nickel-charged 
Nitrilotriacetic Acid (Ni-NTA) beads while other proteins are washed away. IMAC methods 
are well-established and widely used as a method of protein purification. 
 
Back-up Plan 
In case the standard protocol is not successful, fast protein liquid chromatography, or FPLC, 
will be used to purify the synthetic antibody. FPLC is an automated process which 
incorporates a mobile phase and a stationary phase to separate proteins based on affinity. 
Although this process is automated, it is typically used for large-scale purifications, and is 
complicated to program. Thus, IMAC is the preferred method. 
 
Materials and Methods 
Lysate Step 
Purification was conducted individually based on cell type and stock media. The pellet was 
resuspended in 5 mL of lysis buffer, containing PBS, 1 mg/mL lysozyme, 0.5 mM PMSF, 
and 10 mM imidazole. Suspension was transferred to a metal centrifuge tube and incubated 
on ice for 20 minutes. The cells were sonicated at 30% alternating between 6 seconds on and 
59 seconds off for 6 cycles. The lysate was then centrifuged at 4°C and 16,000 rpm for 40 





During centrifugation of the lysate, 250 μL of HisPur​TM​ Ni-NTA beads (Thermo Fisher 
Scientific) were resuspended in 5 mL of wash buffer, containing PBS and 25 mM imidazole. 
This was done for each culture with a volume ratio of 1:1000 for the volume of beads to 
volume of initial culture. The suspension was centrifuged at 2,000 rpm for 4 minutes, 
following which the supernatant was discarded. This process was repeated 3 additional times. 
 
Flow-Through Step 
Using the supernatant of the centrifuged lysate solutions, the Ni-NTA beads were again 
resuspended. To allow the protein to bind to the 6-His tag specific beads, the suspension was 
rocked at 4°C for 1 hour. Centrifugation was conducted at 4°C and 2,000 rpm for 4 minutes. 
At the end, 1 mL of flow-through was saved and stored at -20°C. 
 
Wash Step 
The beads were then washed 5 times. In each wash, the beads were resuspended in wash 
buffer, containing PBS and 25 mM imidazole, rocked for 20 minutes at 4°C, and centrifuged 
at 4°C and 2,000 rpm for 4 minutes. After each wash, 1 mL of wash supernatant was stored 
at -20°C for gel analysis, while the remainder was discarded. 
 
Elution Step 
The elution process was conducted twice, each time resuspending the beads in 200 μL of 
elution buffer, containing PBS and 250 mM imidazole. The suspension was rocked for 20 
minutes at 4°C, then centrifuged at at 4°C and 2,000 rpm for 4 minutes. After, supernatant 






Figure 9.​ ​Representation of protein purification stages. ​Diagram of competitive binding between imidazole 
and 6-His tag to bind Ni-NTA beads 
 
The eight stored samples (1 lysate, 1 flow-through, 5 wash steps, and 2 elutions) for each 
purification conducted were analyzed using SDS-PAGE (GenScript) at 150 volts for 40 
minutes. Visualization was done using Coomassie Brilliant Blue Dye to identify the location 








Figure 10a. Coomassie Brilliant Blue stained SDS-PAGE Gel.​ Gel visualization of eight samples from 
protein purification washing and elution steps, with synthetic antibody band (circled in red) between 25-30kD. 
 
 
Figure 10b. Chemiluminescence image of SDS-PAGE Gel.​ Gel visualization of eight samples and protein 
ladder using chemiluminescence, with synthetic antibody band (circled in red) between 25-30kD. 
 
Figures 10a and 10b show the results of the SDS-PAGE gel in both white light and 
chemiluminescence. Wells 1-4 are from the protein expression of the synthetic antibody 
while wells 6-9 are part of the control experiment that did not have L-DOPA. These wells 




is no antibody in the wash steps because they are all bound to the Ni-NTA beads and it is 
until the elution in well 4 where we see the band at 27kD. This band is due to the increase in 
the imidazole concentration during elution which knocks the antibody off of the Ni-NTA and 
into the supernatant.  
 
Discussion 
The imidazole in the various buffers competes with the 6-His tag on our antibody to bind to 
the Ni-NTA beads due to the similarities in their molecular structure. The imidazole is bound 
to the beads during the initial suspension and competes with the 6-His tag during the various 
washes. The amount of imidazole added to the buffer solutions is inversely proportional to 
the amount of protein that is bound to the Ni-NTA beads. We are able to keep our antibody 
attached to the beads and wash out the impurities before we move on to the elution, which 
knocks the antibody off the bead and allows us to harvest them from the supernatant. We 
used native conditions to purify the synthetic antibody from the solution to keep the protein 
intact through the purification step. In order to limit unspecific binding, we washed the beads 
with wash buffer 5 times and eluted twice to unbind the synthetic antibody from the Ni-NTA 
beads.  
 
The predicted size of our antibody is 27kD and we were able to get a clear band between 
25-30 kD (shown in red circle on Figure 10a and 10b). However, there are still other 
molecules present in our elution which is evident from faint bands above and below our 
target band. This is not an issue because the validation testing that will be conducted is 





Chapter 3: Validation Testing 
 
Introduction 
Validation testing is required to analyze the functionality of the synthetic antibody to ensure 
it has equivalent or greater binding specificity and strength comparable to the current 
standard measure of monoclonal antibodies. Our engineered synthetic antibody must be 
tested to prove that proper incorporation of the unnatural amino acid is accomplished. To do 
this, the K​d​ of both the experimental and control synthetic antibodies to PSA will be 
measured using isothermal titration calorimetry (ITC). The K​d​ value will express the binding 
affinity of the synthetic antibody to PSA. 
 
The specificity and sensitivity of the engineered synthetic antibody to PSA is crucial to 
establish a reliable system with both accuracy and precision. Each of these measures will be 
tested with the use of Western Blot on titrated PSA samples to analyze the experimental 
synthetic antibody compared to anti-PSA monoclonal antibodies. 
 
Materials and Methods 
Specificity Testing 
In the first Western blot, the field will be divided into two sections (with PSA on both sides), 
inserting the monoclonal antibody on the left and the synthetic antibody on the right. Both 
are expected to bind to PSA, which will be visualized as a black band for the monoclonal 
antibody and as a green band for the synthetic antibody carrying GFP. This confirms the 






A second Western blot will be used to verify the sensitivity of the synthetic antibody in 
comparison to the standard sensitivity of the monoclonal antibody. By adding an increased 
concentration of the synthetic antibody to each successive well, the minimum concentration 
of the synthetic antibody needed will be determined. Each successive well, beginning with 
the well containing the minimum concentration for binding, will fluoresce green, indicating 
the lowest concentration needed to bind PSA. Finding that the synthetic antibody has greater 
sensitivity than the monoclonal antibody will confirm that this new detection method is a 
successful replacement of the monoclonal antibody based diagnostic. 
 
Discussion 
It is expected that the binding strength of the experimental synthetic antibody will be 
significantly greater than the control synthetic antibody since the L-DOPA, in the presence of 
sodium periodate, triggers the formation of a covalent bond between the synthetic antibody 
and PSA. Once the K​d​ values of the synthetic antibody are compared to the known binding 
strength of the anti-PSA monoclonal antibodies, which is 1.1 ± 0.2 nM, the requirements of 
binding affinity are satisfied. The experimental synthetic antibody needs to have at least a 
comparable K​d​  in order to be a successful replacement technology for PSA detection. 
 
Based on the current detection measures of PSA, normal conditions are considered to be 
below 2.5 ng/mL, while concentrations of PSA between 2.5 ng/mL and 4.0 ng/mL are 
indicative of prostate cancer. These ranges will be used as a standard in testing the 





Chapter 4: Conclusion 
 
Summary  
This project sought to engineer a synthetic antibody for prostate cancer detection using 
unnatural amino acid incorporation. By circumventing the challenges incurred through the 
use of monoclonal antibodies, this synthetic antibody presents a more efficient and 
cost-effective method to detect prostate cancer. The use of ​E. Coli​ cells as replication 
machinery also eliminates animal welfare concerns, as well as ensures there is no batch to 
batch variability of the synthetic antibodies. Validation testing is currently underway, and 
must be continued to validate that the designed antibody has equal or greater binding affinity 
to PSA. Once verified that the synthetic antibody can accurately and efficiently detect 
prostate cancer with reference to the current monoclonal antibody, this design promises to 
revolutionize prostate cancer diagnostics. 
 
Future Work 
In order to replace current diagnostic techniques with this newly engineered synthetic 
antibody, future work must be done to ensure that non-specific binding does not affect 
measurements of PSA concentrations. This will be done through various assays which will 
test the synthetic antibodies tendencies to bind to various molecules or surfaces. Issues 
caused by non-specific binding can also be ameliorated by introducing various constraints 
which will allow a signal to be emitted only when the synthetic antibody is bound to PSA.  
 
Future Applications 
Both the unnatural amino acid incorporation and synthetic antibody designs present models 
which can be used for a variety of medical and research applications. Unnatural amino acid 
incorporation is a promising new technology; by introducing non-biologically relevant amino 




by L-DOPA’s ability to greatly increase bond strength, expansion of the genetic code through 
this method introduces novel functions into the biological world. The synthetic antibody 
model can also be replicated for countless applications. By replacing monoclonal antibodies 
produced by the hybridoma model, these ​E. Coli​ based synthetic antibodies can ameliorate 






Chapter 5: Ethical Concerns 
 
Traditional monoclonal antibody production is a well known process that has been used to 
create antibodies that have high specificity and binding strength. While these traditional 
production techniques are highly effective, they carry with them two main ethical concerns 
that synthetic antibodies work to address. The first concern centers around animal welfare, as 
the production process requires the antibodies to be produced ​in vivo​.  The second concern is 
the related expenses associated with the current production techniques that have contributed 
to the extremely high cost of traditional monoclonal antibody therapies. 
 
Animals are required for the current production of monoclonal antibodies. While their 
treatment during incubation may be up to current ethical standards, much debate exists 
around the extraction process. Prior to harvesting monoclonal antibodies, the immune 
systems of the animals must be stimulated with a particular disease agent to saturate the 
blood with antibodies. This practice is life-threatening, incurring a high high mortality rate, 
and as such, creates a extensive ethical dilemma for the scientists and companies that employ 
it.  As an alternative, synthetic antibodies are manufactured in ​E. Coli​ which removes the 
animal from the production cycle entirely, thereby eliminating the ethical dilemma 
surrounding production. 
 
The use of animals for production also contributes to the extremely high costs associated 
with traditional monoclonal antibody production.  These high costs severely limit access to 
these antibodies to only the select few who can pay the high price.  These antibodies are an 
incredibly useful tool for researchers and doctors alike, but due to high costs, many 
institutions and research centers shy away from them.  This creates the ethical dilemma 
because many people could be helped by this technology, but due to its high cost, very few 
people can afford to work with or utilize them, severely limiting the scope of research on the 




literature and practice as being low cost, high quality systems.  This would dramatically 
reduce the cost of monoclonal antibodies, allowing for an increase in the scope of research 








Engineering design requires that certain considerations be taken into account before the 
design process begins.  The following factors will be discussed using a framework that 
analyzes the impact each factor has on the project and its stakeholders. 
 
Economic 
Despite this being a project and product focused on saving lives, the economic factors of this 
project must be taken into account when considering the realistic constraints of this project. 
The budget for this project takes into account the funding required to fully carry out all of the 
experiments. The economic advantages of designed synthetic antibodies are apparent when 
discussing large scale antibody production. Traditional antibody production requires large 
investments in resources and animal care facilities to make production viable, but the 
extensive costs associated with these resources and facilities are eventually passed on to the 
patient in the form of high drug costs. Synthetic antibody production, on the other hand, is 
done in ​E. Coli​, which both reduces the cost of small scale testing and makes production 
easily scalable, significantly reducing the costs and resources necessary for production.  This 
makes the synthetic antibody proposed in this paper a less expensive alternative to traditional 
monoclonal antibodies, allowing for greater patient access. 
 
Ethical 
There are two main analyses that must be conducted from an ethical standpoint for this 
project.  The first is to perform a stakeholder analysis. Stakeholders for this project include 




researchers, industry experts and scientists, and academic institutions, and finally the end 
users of the synthetic antibody as patients and those who would be both directly and 
indirectly impacted by the use of the antibodies. The next, and far broader analysis is one that 
involves addressing the ethical concerns, dilemmas, and benefits of these synthetic 
antibodies. The largest benefits of synthetic antibody production come from the cost savings 
associated with a leaner production cycle, and the elimination of animal usage during 
production. These benefits eliminate the two largest ethical concerns for traditional 
monoclonal antibody production. 
 
One of the largest ethical concerns associated with synthetic antibody production is the 
concern of the possibility of using all parts of the process in the production of biological 
weapons.  Screening methods can be repurposed to identify peptides that cause disease or 
physiological disorders. These peptides could then be manufactured using the production 
methods outlined in this paper to produce a bioweapon either in a small, unregulated facility 
or on a large scale for a very low cost. This ethical concern should be understood and 
addressed, but the utilization of the techniques described in this paper to produce a 
bioweapon requires extensive and intimate knowledge of multiple disciplines. This 
knowledge requirement significantly reduces the risk of exploitation of the manufacturing 
methods identified in this paper; however, engineering ethical standards should be 
maintained so as not to cause harm to any of the stakeholders or other members of society 
identified in this section. 
 
Social 
As this project has health and medical implications, social responsibility as it relates to every 
stakeholder identified must be taken into consideration.  The current high cost of monoclonal 
antibodies prevents those stakeholders who do not have the financial means to afford 
antibody treatment from seeking antibody treatment, as insurance companies continue to 




through the introduction of synthetic antibody production would open up access to previously 
expensive treatment regimens to a much larger portion of stakeholders than ever before. 
 
Manufacturability 
This project aimed to validate the manufacturing process outlined in this paper on a small 
scale, with the notion that successes at this scale could be applied to a industrial scale 
manufacturing.  However, it is to be understood that small scale success does not imply that 
the jump to production will be simple. There are several challenges and complications that 
arise when attempting to scale up monoclonal antibody production.  In the traditional 
manufacturing methods, the largest problem is scaling up the animal production facilities 
while maintaining the proper level of quality control in the produced antibodies.  For 
synthetic antibody manufacturing, this quality control challenge is all but eliminated through 
the use of ​E. Coli​ as the production platform.  Large scale bioreactor production of ​E. Coli 
has been thoroughly documented in literature, and has been proven in practice in various 
industrial settings.  These previous successes significantly improve the possibility of a 
successful scale-up of the manufacturing procedures verified through this project. 
 
Health and Safety 
Ensuring the health and safety of all stakeholders involved in the project is of the utmost 
importance at all phases of the product.  For the small scale production detailed in this paper, 
all team members passed the Santa Clara University Laboratory Safety Protocol and 
Procedures exam.  This ensured the execution of the manufacturing plan in a proper lab 
setting where all risks associated with the materials and procedures used in this project were 
minimized.  Members also had previous lab experience performing various laboratory 
procedures, and as such were well trained in the handling of hazardous materials. 
 
To protect the health and safety of the stakeholders undergoing treatments using these 




purpose.  In the case of the project described in this paper, the specific antibody being 
developed has the sole purpose of detecting the PSA biomarker.  As such, the synthetic 
antibody outlined in this paper should not be used to detect other biomarkers possibly present 
in stakeholders undergoing treatment.  Adherence to this principle will help ensure the health 
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Appendix I. ​L-DOPA and Tyrosine Structures 
 
 
L-DOPA 
 
 
Tyrosine 
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